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ARTICLE
Checkpoint blockade immunotherapy reshapes the
high-dimensional phenotypic heterogeneity of
murine intratumoural neoantigen-speciﬁc CD8+
T cells
M. Fehlings 1, Y. Simoni1, H.L. Penny1, E. Becht1, C.Y. Loh1, M.M. Gubin2, J.P. Ward2, S.C. Wong 1,
R.D. Schreiber2 & E.W. Newell 1
The analysis of neoantigen-speciﬁc CD8+ T cells in tumour-bearing individuals is challenging
due to the small pool of tumour antigen-speciﬁc T cells. Here we show that mass cytometry
with multiplex combinatorial tetramer staining can identify and characterize neoantigen-
speciﬁc CD8+ T cells in mice bearing T3 methylcholanthrene-induced sarcomas that are
susceptible to checkpoint blockade immunotherapy. Among 81 candidate antigens tested, we
identify T cells restricted to two known neoantigens simultaneously in tumours, spleens and
lymph nodes in tumour-bearing mice. High-dimensional phenotypic proﬁling reveals that
antigen-speciﬁc, tumour-inﬁltrating T cells are highly heterogeneous. We further show that
neoantigen-speciﬁc T cells display a different phenotypic proﬁle in mice treated with anti-
CTLA-4 or anti-PD-1 immunotherapy, whereas their peripheral counterparts are not affected
by the treatments. Our results provide insights into the nature of neoantigen-speciﬁc T cells
and the effects of checkpoint blockade immunotherapy.
DOI: 10.1038/s41467-017-00627-z OPEN
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The importance of CD8
+ cytotoxic T lymphocytes in anti-
tumour responses is well established but has come under
intense scrutiny given advances in our understanding of
the basic principles governing spontaneous anti-tumour respon-
ses in mice and the successes of various cancer immunotherapy
trials in humans. To combat outgrowth of tumours, CD8+ T cells
detect tumour antigens that are displayed in the context of major
histocompatibility complex class I (MHC-I) molecules on the
surface of transformed cells. In addition to tumour-associated
self-antigens and cancer germline antigens, tumour-speciﬁc
mutant antigens (neoantigens), arising from carcinogen expo-
sure or other causes of genomic mutations, represent a third
major class of antigens that are expressed by cancer cells
(reviewed in refs 1, 2). Studies in mice showed that tumour
neoantigens can be rapidly identiﬁed using genomic and bioin-
formatic approaches3, 4 and can be used in personalized vaccines
to effectively eliminate growing cancers in mice5, 6. Subsequent
human studies revealed that tumour-speciﬁc immune responses
can also be boosted or induced using similar neoantigen-based
cancer vaccine approaches7, 8. Previously we (M.M.G, J.P.W. and
R.D.S.) used immunogenomic approaches to identify two
immunodominant neoantigens, mutant Lama4 (mLama4) and
mutant Alg8 (mAlg8), in T3 methylcholanthrene (MCA)-induced
sarcoma cells. We showed that these epitopes render mice bearing
progressively growing tumours susceptible to tumour rejection
following treatment with anti-CTLA-4 and/or anti-PD-1. This
study demonstrated that neoantigens are the favoured targets of
T cells reinvigorated by checkpoint blockade therapy, that vac-
cines generated with immunodominant neoantigens are as
effective as checkpoint blockade in inducing therapeutic tumour
rejection, and that tumour neoantigen-speciﬁc T cells display
distinct transcriptomic signatures that reﬂect the type of immu-
notherapy applied to the tumour-bearing host (i.e., control
monoclonal antibody (mAb) (exhausted CD8+ T cells), anti-PD-1
(change in T-cell metabolism), anti-CTLA-4 (increased priming/
proliferation) or the combination of anti-PD-1 and anti-CTLA-4
(increased effector function))5.
In humans, CTLA-4 blockade results in an enhanced
neoantigen-speciﬁc T-cell response9 and broadened melanoma
antigen repertoire10. Other studies demonstrated a correlation
between the beneﬁts of checkpoint blockade immunotherapy and
the mutational burden in patients with melanoma and non-small
cell lung cancer11–13, and showed that patients with tumours
enriched for clonal neoantigens have increased sensitivity to anti-
PD-1/anti-CTLA-4 immunotherapy14. As a result, neoantigens
are currently considered promising targets for personalized can-
cer immunotherapy1.
Although in silico pipelines exist that are capable of success-
fully predicting non-synonymous mutations that can give rise to
tumour-speciﬁc neoantigens2, 15, it is not clear how accurate these
methods are, given that T-cell epitope usage can be inﬂuenced by
many factors16. Mass cytometry (a.k.a. cytometry by time of
ﬂight, CyTOF 17–19) in conjunction with peptide-MHC tetramer
staining5, 15, 20–22 has been shown to facilitate broad MHC-I
epitope mapping, with a theoretical possibility of simultaneously
assessing >1,000 T-cell antigen speciﬁcities with high sensitivity
for rare antigen-speciﬁc T cells and concurrent in-depth char-
acterization of these cells at the single-cell level23.
Here we employ the full capacity of mass cytometry through
the use of combinatorial tetramer staining together with cellular
barcoding and high dimensional cellular phenotypic analysis to
assess T cells targeting 81 different candidate tumour antigens in
mice bearing a progressively growing MCA-induced sarcoma that
is susceptible to checkpoint blockade immunotherapy5. This
allows us to identify neoantigen-speciﬁc CD8+ T cells and to
characterize such cells simultaneously in tumours, spleens,
draining- and non-draining lymph nodes from tumour-bearing
hosts. By using high-performance dimensional reduction meth-
odology24–27, we further proﬁle neoantigen-speciﬁc, tumour-
inﬁltrating CD8+ T cells and assess the effects of anti-CTLA-4
and anti-PD-1 therapy on these cells and their peripheral
counterparts.
Results
Identiﬁcation of neoantigen-speciﬁc T cells. To identify
neoantigen-speciﬁc CD8+ T cells in tumours as well as in per-
ipheral tissues (i.e., spleens, draining and non-draining lymph
nodes) of MCA sarcoma-bearing mice by mass cytometry, we set
up a three metal combinatorial tetramer staining approach as
described previously23. In addition to the dominant d42m1-T3
MCA-induced sarcoma mutant tumour epitopes mLama4 and
mAlg8, we (M.M.G., J.P.W. and R.D.S.) previously reported to be
expressed in T3, we included another set of 79 H-2Kb-restricted
predicted tumour epitope candidates (Fig. 1a and Supplementary
Table 1)5. Single-cell suspensions from tumours, spleens, draining
and non-draining lymph nodes were obtained 12 days (the time
point previously reported for peak values of antigen-speciﬁc
tumour-inﬁltrating lymphocytes (TILs) before tumour rejection5)
after tumour cell inoculation and probed simultaneously for all 81
potential T-cell speciﬁcities, while staining with 28 different
antibodies for the further identiﬁcation and characterization of
CD8+ T cells (Supplementary Fig. 1B and Supplementary
Table 2). Subsequent cellular barcoding facilitated the simulta-
neous acquisition of the cells derived from each tissue
compartment28.
For the identiﬁcation of antigen-speciﬁc, tetramer triple-
positive cells, we gated on live immune cells (cisplatin–, DNA+
CD45+), excluded B cells (CD19+) and selected TCR-beta+,
CD90+, CD8+ and CD4– cells (Supplementary Fig. 1A), and used
an automated combinatorial peptide-MHC gating strategy23,
which was further conﬁrmed by manual standard biaxial gating
(Fig. 1b). Antigen speciﬁcity was deﬁned by a standardized cutoff
of >0.15 % of total CD8+ T cells.
Consistent with previously published data5, we identiﬁed
substantial numbers of CD8+ T cells restricted to two prevailing
mutant tumour epitopes, mLama4 (10.2± 3.2% as the
mean± SEM of ﬁve experiments) and mAlg8 (9.9± 3.8% as the
mean± SEM of ﬁve experiments), inﬁltrating the tumours of
tumour-bearing mice. In addition, we were able to detect CD8+
T cells reacting with tetramers speciﬁc for both epitopes in
spleens (mLama4: 0.8± 0.2%; mAlg8 0.6± 0.2% as the
mean± SEM of ﬁve experiments), draining lymph nodes
(mLama4: 1± 0.2%; mAlg8 0.3± 0.1% as the mean± SEM of
ﬁve experiments), as well as non-draining lymph nodes
(mLama4: 0.4± 0.1%; mAlg8 0.2± 0.03% as the mean± SEM of
ﬁve experiments) from the same group of animals. We did not
track CD8+ T cells restricted to any of the other 79 potential
tumour H-2Kb-restricted mutant epitope candidates (Fig. 1a) or
controls (SIINFEKL) consistently across the different types of
tissues. Moreover, none of the predicted epitope candidates was
found in spleens or lymph nodes from wild-type non-tumour-
bearing animals.
We next interrogated the phenotypes of T cells from each
tissue by summarizing the expression proﬁles of molecules
associated with CD8+ T-cell differentiation (CD62L and CD44)29
activation/stimulation (ICOS)30, recruitment/trafﬁcking (CXCR-3)31
and exhaustion/dysfunction (Tim-3 and PD-1)32, 33. We observed
numerous phenotypic variations in the CD8+ T-cell populations
across tissues, which validated our antibody staining. For
instance, CD44 is upregulated on antigen-experienced cells
after activation34 and we detected the highest frequencies of
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00627-z
2 NATURE COMMUNICATIONS |8:  562 |DOI: 10.1038/s41467-017-00627-z |www.nature.com/naturecommunications
CD44-positive cells in tumours. In contrast, we found higher
numbers of T cells expressing CD62L and CXCR3 in the
periphery, the latter which has recently been shown to be
required for CD8+ T-cell trafﬁcking towards melanomas in vivo35
(Fig. 1c). In contrast to their peripheral counterparts, large
numbers of tetramer positive cells inﬁltrating the tumours also
expressed PD-1 and Tim-3, and these markers could only be
identiﬁed on a very low percentage of antigen-speciﬁc T cells in
the periphery of tumour-bearing animals (Fig. 1c, d). These data
demonstrate that mass cytometry together with a combinatorial
tetramer staining approach can be used to comprehensively
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targeting a broad range of predicted epitope candidates
simultaneously across multiple tissues.
Effects of anti-CTLA-4 immunotherapy on T-cell frequencies.
Administration of anti-CTLA-4 antibodies was demonstrated to
result in a CD8+ T-cell-dependent tumour rejection and treat-
ment doubled the numbers of mLama4- and mAlg8-speciﬁc
T cells inﬁltrating the tumours of MCA sarcoma-bearing mice5.
This prompted us to assess whether CTLA-4 blocking also affects
the magnitude of those antigen-speciﬁc CD8+ T cells in spleens,
draining and non-draining lymph nodes of tumour-bearing mice.
Moreover, as anti-CTLA-4 treatment has recently been shown to
broaden the T-cell repertoire in melanoma patients10, we wanted
to assess whether CTLA-4-blocking primes and gives rise to
T-cell responses against predicted antigen candidates that are not
present in untreated tumour-bearing animals.
We detected a signiﬁcant increase in the magnitude of
mLama4- (~2-fold) and mAlg8- (~1.5-fold) speciﬁc T-cell
responses in tumours from mice that received anti-CTLA-4
mAbs (Fig. 1e). The frequencies of T cells restricted to these
immunodominant antigens found in the peripheral compart-
ments, however, remained unaltered and we did not observe
signiﬁcant differences in frequencies of such T cells in the spleens
or lymph nodes of tumour-bearing mice undergoing immu-
notherapy (Fig. 1e). Among all epitopes tested, we were not able
to identify novel antigen-speciﬁcities (>0.15%) both in tumours
or in the peripheral circulation of anti-CTLA-4-treated mice that
were not also seen in isotype mAb-treated mice. These results
suggest that anti-CTLA-4 treatment induces increased prolifera-
tion of neoantigen-speciﬁc T cells selectively in the tumour.
In-depth proﬁling of antigen-speciﬁc TILs. We next inter-
rogated phenotypic alterations of mLama4- and mAlg8-speciﬁc
T cells that were related to anti-CTLA-4 treatment. Although
phenotypic and functional changes of antigen-speciﬁc TILs in
response to immunotherapy have previously been described, it
was either by assessing the expression of single marker molecules
or by assessing gene expression proﬁles of sorted cell popula-
tions5. Being able to simultaneously interrogate 28 relevant sur-
face molecules at the single-cell level by using the remaining
antibodies of the tetramer staining panel, we were able to deeply
proﬁle these cells and analysed their phenotypes by applying the
t-distributed stochastic neighbour embedding (t-SNE) algo-
rithm24–26. By mapping cells with similar phenotypes to nearby
points into a two-dimensional space, t-SNE disentangles distinct
cellular subsets and reduces the high dimensionality of the mass
cytometry data into two dimensions, while retaining the overall
cellular relationships. We combined the data acquired for
mLama4- and mAlg8-speciﬁc TILs from tumour-bearing mice
undergoing anti-CTLA-4 treatment together with data acquired
from isotype mAb-treated mice to produce an overall map of all
observed phenotypic proﬁles of tumour-speciﬁc TILs. Using these
criteria and the resulting two-dimensional t-SNE dot plot, we
were able to visually detect several distinct cell clusters of all
possible phenotypes observed from tumour-speciﬁc T cells
derived from tumours (Fig. 2a). The phenotypes of these clusters,
in terms of median expression levels of each marker assessed,
were summarized as heat plots for each cluster (Fig. 2a). Based on
these plots, we delineated ten different phenotypic clusters of
antigen-speciﬁc T cells that are composed of cells speciﬁc for
either neoantigen derived from anti-CTLA-4 treated and isotype
control treated tumour bearing subjects (Fig. 2a).
Based on the clusters of cells identiﬁed using t-SNE analysis, a
gating strategy using standard biaxial plots was devised. This
allowed us to construct working deﬁnitions for each of these cell
clusters (Fig. 2b). By plotting PD-1 vs. KLRG-1 we were able to
identify clusters three (C3), four (C4) and ﬁve (C5) according to
their high PD-1 and their absence of KLRG-1 expression.
Although all three clusters were also positive for Sca-1, C3 was
negative for Tim-3, and C4 as well as C5 could further be
distinguished according to their expression intensities for Tim-3
and CD39. Cluster 6 (C6) and 10 (C10) constituted KLRG-1-
positive cells and could further be subdivided based on their Sca-1
and Tim-3 expression proﬁles. PD-1 and KLRG-1-negative cells
were delineated into cluster one (C1) and two (C2), as well as
clusters seven (C7), eight (C8) and nine (C9) according to their
Sca-1 and Tim-3 expression levels. Clusters C1 and C2 were Sca-1
negative but exhibited differential CD27 expression, whereas C7,
C8 and C9 expressed Sca-1 but showed differential expression
levels of Tim-3 and CD160, respectively (Fig. 2b).
Elevated expression levels of PD-1, Lag-3 and Tim-3 on
mLama4 and mAlg8-speciﬁc TILs cells have previously been
linked to a dysfunctional phenotype that is accompanied by
severe functional deﬁcits of these cells5. According to the
expression intensities of these markers found on the cells within
the clusters segregated by t-SNE, clusters C3, C4 and C5 appeared
to comprise such dysfunctional T cells albeit to varying degrees,
whereas cluster C2 did not express any of the signature markers
(Fig. 2c). Notably, we also observed high expression levels of
GITR—a molecule that has been shown to be involved in tumour
immunity36, 37—on all cells that were restricted to clusters C3,
C4, and C5.
These results collectively demonstrate that t-SNE is able to
segregate antigen-speciﬁc TILs derived from anti-CTLA-4 treated
and control mice into several distinct clusters, thus revealing a
remarkable variation in the phenotypes of these neoantigen-
speciﬁc TILs.
Antigen-speciﬁc TILs constitute a heterogeneous population.
To characterize the phenotypes of the antigen-speciﬁc TILs, we
focused ﬁrst on data from tumour-bearing mice that did not
undergo CTLA-4 blockade. From this analysis, we observed that
Fig. 1 Analysis of neoantigen-speciﬁc T cells in tumours and periphery. a Screening for CD8+ T cells targeting 81 potential mutant peptide–MHC complexes
by a combinatorial peptide–MHC tetramer staining approach identiﬁed signiﬁcant numbers of CD8+ T cells restricted to two major mutant epitopes,
mutant Lama4 (mLama4) and mutant Alg8 (mAlg8), simultaneously in tumours, spleens, draining lymph nodes and non-draining lymph nodes of tumour-
bearing mice. Data are average frequencies from at least three independent experiments. b Representative example for a triple-coded tetramer staining
from the draining lymph nodes to identify antigen-speciﬁc CD8+ T cells. T cells speciﬁc for mLama4 were identiﬁed by tetramers labelled with Gd-157,
Tb-159 Di and Yb-173 elements (0.89%), whereas mAlg8-positive cells were identiﬁed by tetramers labelled with Dy-163, Tm-169 and Yb-173 elements
(0.23%). c Representative example for phenotypes of tetramer-positive (mLama4 and mAlg8) and tetramer-negative (Tetneg) CD8+ T cells from tumours,
spleens and lymph nodes of tumour-bearing mice. d Percentages of mLama-4 and mAlg8-speciﬁc CD8+ T cells expressing PD-1 and Tim-3 in tumours,
spleen, draining lymph nodes (dLN) and non-draining lymph nodes (ndLN). Data are means± SEM of ﬁve independent experiments. *p< 0.05 by t-test
corrected for multiple comparisons with Holm–Sidak procedure. e Frequencies of mLama4-speciﬁc CD8+ T and mAlg8-speciﬁc CD8+ T cells from tumours,
spleen, draining and non-draining lymph nodes of tumour-bearing mice treated with anti-CTLA-4 or isotype control mAbs. Data are means± SEM of at
least ﬁve independent experiments. *p< 0.05 by t-test corrected for multiple comparisons with Holm–Sidak procedure
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T cells speciﬁc for either antigen could be subdivided into several
clusters thus representing a heterogeneous cell population
amongst T cells that were restricted to a single tumour epitope
(Fig. 3a). Among the 10 different clusters identiﬁed by t-SNE as
described above, the majority of T cells from untreated tumour
bearing mice could be found within clusters C1–C6 (black circled,
with a frequency >10% for either one of the two antigen speci-
ﬁcities), whereas lesser cells speciﬁc for either epitope were found
to be distributed across clusters C7–C10 (grey circled). In parti-
cular, whereas the majority of mLama4-speciﬁc T cells could be
detected within C1–C3, we found the highest frequencies of
mAlg8-speciﬁc T cells to be present in C3–C6. To validate the
existence of different phenotypic clusters among tumour-speciﬁc
T cells that were disentangled from the high dimensional data set
by using the t-SNE algorithm, we further designed a ﬂow cyto-
metry panel that allowed us to delineate the predominant T-cell
clusters (C1–C6) at comparable frequencies (Supplementary
Fig. 2A) in untreated tumour-bearing mice according to the
sorting strategy described in Fig. 2b. Owing to limitations in the
number of markers available for these stainings, we were not able
to clearly separate cluster four (C4) from cluster ﬁve (C5) and
therefore combined the two clusters to be able to compare these
stainings with the data obtained from the high-dimensional mass





















































































































































Fig. 2 Neoantigen-speciﬁc TILs display different phenotypes. Analysis was performed on a combined data set from tumour inﬁltrating T cells speciﬁc for
mLama4 and mAlg8 of mice treated with anti-CTLA-4 and from mice treated with control (isotype) mAbs. aManual gating on antigen-speciﬁc CD8+ T-cell
clusters segregated by t-SNE identiﬁed a total of 10 different clusters. The median expression intensities for each of the markers probed were plotted for all
clusters observed and summarized as heat map. b Representation of the different phenotypic clusters delineated by t-SNE using a sequential biaxial dot
plot gating strategy on signature markers characteristic for each cluster. c Histograms showing clusters with differential expression levels of markers
associated with T-cell dysfunction (PD-1, Lag-3, Tim-3 and CD160) and GITR. Cluster 2 (C2) served as analogue
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mAlg8-specific CD8+ T cells
Fig. 3 Heterogeneity of tumour-speciﬁc TILs changes following treatment. a The majority of antigen-speciﬁc T cells from untreated tumour-bearing mice
can be identiﬁed within six clusters (C1–C6) segregated by t-SNE. mLama4 and mAlg8-speciﬁc T cells are unequally distributed with different percentages
of cells found in the individual clusters (n= 5 mice per group). b The distribution pattern of mLama4 and mAlg8- speciﬁc TILs within the corresponding
clusters is consistent across independent experiments. Percentage differences of mLama4- and mAlg8-speciﬁc TILs positive for the marker constellation
that identify each of the clusters segregated by t-SNE (p= 0.008, Fisher’s exact test: n= 5). c Median ﬂuorescence intensities and percentages of cells
show comparable levels of Ki-67 but differences in granzyme B expression within distinct antigen-speciﬁc T cell clusters. CD8+ T cells from naïve spleens
served as controls. Data are means± SEM of at least three independent experiments. *p< 0.05 by t-test corrected for multiple comparisons with
Holm–Sidak procedure. d Anti-CTLA-4 treatment shifts mLama4- and mAlg8-speciﬁc TILS from clusters C1–C5 towards clusters C7-C10 on the t-SNE plot.
e Anti-CTLA-4 treatment of tumour bearing mice decreases the number of PD1+ GITR+ mLama4- and mAlg8-speciﬁc TILs and enhances Sca-1 expression
on cells speciﬁc for either epitope (n= 5 mice per group). f mLama4- and mAlg8-speciﬁc T cells display higher frequencies of markers associated with
cluster C7-C10 following anti-CTLA-4 treatment as compared to their control (isotype) mAbs treated counterparts and show comparable percentages
amongst both antigen speciﬁcities. Data are means± SEM of ﬁve independent experiments
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segregate these clusters on a two-dimensional map albeit to a
lesser degree due to the complexity restrictions associated with
the ﬂow cyometry staining panel (Supplementary Fig. 2B).
Notably, by applying these stainings on tumours from individual
mice, we further eliminated the possibility that the heterogeneity
observed resulted from the pooling of several tumours required
for the analysis by the mass cytometer.
Although T cells restricted to mLama4 or mAlg8 partly
overlapped, they did not entirely cluster together. We noted
remarkable differences in the cluster frequencies corresponding to
the different antigen speciﬁcities. A higher percentage of
mLama4-speciﬁc T cells were found within clusters C1, C2 and
C3, which are represented by a KLRG-1−, PD-1− phenotype (C1
and C2), as well as KLRG-1−, PD-1+ cells (C3). In contrast, higher
percentages of mAlg8-specifc cells could be detected in clusters
C4, C5 and C6, which are characterized by cells expressing both
Tim-3 and PD-1 (C4 and C5), as well as cells that expressed
KLRG-1 (C6) (Fig. 3a). Based on these deﬁnitions, we found these
differences in phenotypic patterns between both antigen speciﬁ-
cities observed to be consistent across independent experiments
(Fig. 3b).
CTLA-4 blocking in tumour-bearing mice resulted in higher
frequencies of mLama4- and mAlg8-speciﬁc T cells. To assess
whether phenotypically different antigen-speciﬁc TILs derived
from untreated tumour bearing mice differed in proliferation, we
evaluated Ki-67 expression in cells derived from the distinct
clusters by conventional ﬂow cytometry. In addition, we
evaluated the capacities of these cells to express granzyme B to
assess their functional status. We found that approximately half
of the cells present in each of the clusters were positive for Ki-67.
However, we did not observe signiﬁcant differences in the
proliferation levels of these cells amongst the clusters (Fig. 3c). In
contrast, whereas the majority of the clusters were characterized
by a low expression of granzyme B, we detected signiﬁcantly
higher expression levels within cluster four and ﬁve as compared
to the other clusters (Fig. 3c).
In conclusion, antigen-speciﬁc TILs constituted a heteroge-
neous cell population and T cells restricted to distinct mutant
tumour epitopes exhibited unique phenotypic with different
functional characteristics.
CTLA-4 blocking drives T cells towards a similar phenotype.
Next, we studied the phenotypes of neoantigen-speciﬁc T cells
derived from tumour-bearing mice that underwent anti-CTLA-4
checkpoint blockade immunotherapy. This analysis was striking
in that cells occupying regions C1–C5 were mostly absent in
tumours from these treated mice. Instead, the majority of the
neoantigen-speciﬁc T cells were found in clusters C7–C10 and the
frequency distributions were similar for both antigen speciﬁcities
(Fig. 3d). Despite differential expression levels of markers asso-
ciated with dysfunction, cells within clusters C3–C5 corresponded
to cells with a PD-1+ GITR+ phenotype (refer to Fig. 2a). CTLA-4
blocking greatly reduced the frequencies of cells in clusters
C3–C5 and thus nearly eliminated the cells expressing markers
associated with T-cell dysfunction (e.g., PD-1 and Tim-3)
(Fig. 3d). By using standard biaxial gating, we further conﬁrmed
that anti-CTLA-4 treatment resulted in increased numbers of
mLama4- and mAlg8-speciﬁc TILs that display low PD-1 and low
GITR expression levels (Fig. 3e). In addition, these cells exhibited
a high expression of Sca-1.
We (M.M.G., J.P.W. and R.D.S.) have previously shown that
besides CTLA-4 blocking, anti-PD-1 treatment rendered
neoantigen-speciﬁc T cells capable of tumour rejection. To assess
whether this also comes along with such a massive phenotypic
alteration, we performed our high-dimensional proﬁling
approach on mLama4-speciﬁc TILs from mice that underwent
anti-PD-1 treatment or remained untreated (isotype control).
Likewise, we observed a dramatic shift of different tumour-
speciﬁc T-cell clusters towards a new position on a two-
dimensional t-SNE plot. Similar to changes induced by CTLA-4
blocking, we detected several alterations in the expression
patterns of the different marker molecules assessed, in particular
a substantial reduced expression of markers that are associated
with a dysfunctional T-cell phenotype as well as an upregulation
of Sca-1 (Supplementary Fig 3A).
The appearance of distinct clusters with comparable frequen-
cies amongst mLama4- and mAlg8-speciﬁc T cells following anti-
CTLA-4 mAbs therapy suggested that treatment induced
neoantigen-speciﬁc TILs to acquire a similar phenotypic proﬁle
that also lacks the expression of markers associated with
dysfunction. Indeed, when we compared the phenotypic char-
acteristics of these cells with and without anti-CTLA-4 treatment
across different experiments, we were able to detect higher
frequencies of T cells exhibiting a PD-1− and GITR− phenotype
regardless of their epitope restrictions (Fig. 3f). According to their
phenotypic proﬁles, C7–10 can be classiﬁed as clusters composed
of cells that express high levels of Sca-1 and low levels of PD-1
(refer to Fig. 2a). Compared with cells derived from isotype
control mAb-treated tumour-bearing mice, we observed higher
numbers of those cells with comparable percentages amongst the
two antigen speciﬁcities (Fig. 3f). In addition, cells in C10 are
associated with high KLRG-1 expression and a higher number of
mLama4- and mAlg8-speciﬁc T cells with similar frequencies
could be detected as compared with their isotype control mAb-
treated counterparts. We found that KLRG-1 expression is also
associated with C6 and we found cells displaying C6-like
characteristics among T cells speciﬁc for mAlg8 after immu-
notherapy at comparable levels to the frequencies of mAlg8-
speciﬁc T cells derived from isotype control treated tumour
bearing animals.
These data show that cancer immunotherapy in this mouse
model induced dramatic phenotypic alterations of neoantigen-
speciﬁc T cells. Moreover, T cells with different epitope usage
acquired a similar phenotype that lacked surface molecules
associated with T-cell dysfunction.
Immunotherapy affects TILs but not peripheral T cells. To
determine whether the phenotypic alterations of mLama4- and
mAlg8-speciﬁc TILs also occurred in the periphery of anti-CTLA-
4-treated tumour-bearing mice, we used data derived from per-
ipheral CD8+ T cells to broadly analyse the resultant changes in
the dominant neoantigen-speciﬁc CD8+ T-cell population from
the two treatment groups using the aforementioned t-SNE-based
dimensionality reduction approach. Owing to low frequencies of
antigen-speciﬁc T cells found in each of these peripheral tissues
assessed and to allow for comparisons of the phenotypes of bulk
CD8+ T cells inﬁltrating the tumours, we also included tetramer-
negative CD8+ T cells for this analysis. Notably, although the
majority of tetramer-negative CD8+ T cells isolated from tumours
were phenotypically distinct from their antigen-speciﬁc counter-
parts, we detected a partial overlap between tetramer-positive and
negative cells on the two-dimensional t-SNE plot. We categorized
a total of four clusters that showed different percentages of all
TILs, and that could further be characterized according to the
differential expression proﬁles of the marker molecules assessed
(Supplementary Fig. 4A–C).
In contrast to mLama4- and mAlg8-speciﬁc TILs, very little
phenotypic alterations were observed when comparing
neoantigen-speciﬁc cells derived from peripheral tissues of
isotype vs. anti-CLTA-4 mAb-treated mice. Whereas phenotypic
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changes in antigen-speciﬁc TILs from mice treated with anti-
CTLA-4 mAbs were reﬂected by a remarkable shift in their
positions occupied on the two-dimensional t-SNE plot (Fig. 4a),
we did not detect substantial differences in the cluster regions
occupied by lymph node- or spleen-derived T cells speciﬁc for
either antigen when cells were obtained from mice that under-
went anti-CTLA-4 treatment (Fig. 4a and Supplementary Fig. 5).
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Fig. 4 CTLA-4 blocking affects phenotypes of neoantigen-speciﬁc TILs. a Visualized t-SNE map highlighting the distribution of tetramer positive antigen-
speciﬁc T cells and tetramer-negative cells within tumours and draining lymph nodes (as representative for the periphery). T-cell clusters speciﬁc for
mLama4 or mAlg8 from the draining lymph node can be identiﬁed within similar locations on a two-dimensional t-SNE plot, irrespectively of anti-CTLA-4
or control (isotype) mAbs treatment, whereas antigen-speciﬁc CD8+ T cells from tumours are localized within different areas following immunotherapy
(n= 5 mice per group). b Heat plot of the relative expression of each marker molecule assessed for mAlg8- and mLama4-speciﬁc CD8+ T cells
simultaneously in lymph nodes, spleens and tumours from anti-CTLA-4 and control (isotype) mAbs treated tumour-bearing mice. Shown are the average
z-scores from ﬁve independent experiments. *p< 0.05 by t-test and BH correction using a false discovery rate of 0.25
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position of tumour-inﬁltrating mLama4-reactive cells in mice that
underwent anti-PD-1 therapy, we did not make such observations
in the lymph nodes from these mice (Supplementary Fig. 3b).
These ﬁndings suggest that the major effects of immunother-
apy on T-cell phenotypes were restricted to neoantigen-speciﬁc
T cells inﬁltrating the tumour. To further objectively compare the
phenotypic proﬁles of tumour speciﬁc cells derived from tumour
vs. periphery with and without anti-CTLA4 treatment across
separate experiments, we averaged the median expression
intensities from independent experiments (n= 5) for each of
the non-lineage molecules assessed and calculated z-scores for
each phenotypic marker and averaged them for each T-cell
speciﬁcity as previously described23. We represented the data as
heat plots to meaningfully assess differences in phenotypic
proﬁles of mLama4- and mAlg8-reactive cells in the distinct
tissues of mice treated with either isotype control or anti-CTLA-4
mAbs. Within the tumours of treated animals, CTLA-4 blockade
gave rise to a signiﬁcantly altered expression of markers
associated with dysfunction (PD-1, Lag-3 and CD160), activation
(CD25, GITR and CD38), as well as co-stimulation and
development (CD27 and CD127) on mLama4-speciﬁc T cells.
Similar ﬁndings were obtained when we interrogated the marker
expression of mAlg8-restricted T cells across the different tissues
(Fig. 4b). From these heat plots, it was also apparent that the
phenotypes of peripheral CD8+ T cells speciﬁc for either antigen,
unlike neoantigen-speciﬁc TILs, were not inﬂuenced by anti-
CTLA-4 immunotherapy, as no differences were observed in the
expression of any of the marker molecules assessed simulta-
neously in the spleens and draining and non-draining lymph
nodes. Likewise, we did not observe remarkable or statistically
signiﬁcant differences in the phenotypes of tetramer negative cells
found within the tumours in response to anti-CTLA-4 treatment
(Fig. 4b).
Collectively, we show that checkpoint blockade immunother-
apy in this mouse model did not profoundly inﬂuence the
phenotypic proﬁles of peripheral neoantigen-speciﬁc CD8+
T cells but predominantly affected marker expression of
antigen-experienced T cells present in the tumour. Although
resulting from a short-term transplant model, these data suggest
that neoantigen-speciﬁc TILs may be generally more susceptible
to immunotherapy than their peripheral counterparts.
Discussion
Accumulating data suggest that neoantigens are relevant targets
for personalized anti-cancer therapies. Here we used mass cyto-
metry analysis in combination with a multiplex combinatorial
tetramer staining approach23 to screen for CD8+ T cells targeting
a broad range of antigen candidates across tissues from mice
bearing progressively growing MCA-induced sarcomas that are
susceptible to checkpoint blockade immunotherapy.
Similar to our (M.M.G., J.P.W. and R.D.S.) previous ﬁndings5,
we found that neoantigen-speciﬁc TILs had a higher frequency of
cells that co-expressed PD-1 and Tim-3 than tetramer-negative
CD8+ TILs. In addition, these cells also had higher expression
levels of the PD-1 and Tim-3 markers, which is in line with a
previous independent report using a MC38 colorectal cancer
model where antigen-speciﬁc TILs displayed a more
exhausted-like phenotype than bulk CD8+ TILs6. In contrast to a
recent CT-26 tumour study, where also lymph node-derived
tumour antigen-speciﬁc T cells showed upregulated PD-1
expression38, we only observed small numbers of PD-1-positive
antigen-speciﬁc T cells in the peripheral compartments,
suggesting that these cells are not being exposed to continual
antigen exposure39 or were disarmed by the suppressive tumour
microenvironment40.
We detected several tumour-inﬁltrating T cells that were not
speciﬁc for mLama4, mAlg8 or any other epitope tested here.
Interestingly, we found that their phenotypic proﬁles overlapped
only partially with T cells that are restricted to the immunodo-
minant epitopes. Whether these cells may be speciﬁc for other
tumour-derived antigens is currently unclear. This highlights the
potential utility of our approach in extending the screen for other
possible antigens being targeted by these cells.
Consistent with previous ﬁndings, we detected an increase in
the magnitude of mLama4- and mAlg8-speciﬁc TILs following
anti-CTLA-4 immunotherapy, while the peripheral counterparts
were not affected. CTLA-4 blocking has been shown to enhance
priming of responsive T cells41 and in a recent study on blood
samples derived from melanoma patients it was shown that anti-
CTLA-4 immunotherapy can broaden the range of antigens being
targeted by the T-cell repertoire10. We did not detect the
appearance of novel T-cell speciﬁcities against any of the epitope
candidates tested here, thus suggesting a CTLA-4-dependent
tumour-speciﬁc effect on the two dominant antigen-speciﬁc
T cells in this model.
By using t-SNE dimensionality reduction, we provide a detailed
insight into the phenotypes of antigen-speciﬁc TILs from mice
treated with checkpoint blockade or control mAbs. The delinea-
tion of 10 clusters in our analysis allowed us to investigate an in-
depth picture of neoantigen-speciﬁc CD8+ T cells diversity. We
validated that the manual cluster delineation used here was not
arbitrary, as we detected a similar clustering scheme when we
applied an automated clustering method (see Methods). More-
over, using manual gating we were able to further disentangle
subtle differences between some of the clusters that were not
revealed when applying automated clustering. This approach
enabled us to broadly assess the composition of tumour-speciﬁc
T cells and to describe and validate a remarkable degree of
phenotypic heterogeneity within neoantigen-speciﬁc T cells in
this model system.
The complexity of antigen-speciﬁc T cells has been described
for viral antigens in humans and proposed to be necessary in
order to achieve an adequate ﬂexibility in anti-pathogen
responses19. The detection of different phenotypic patterns
among neoantigen-speciﬁc T cells suggests a dissimilar func-
tionality of such T cells in the anti-tumour response. This was
further corroborated by the fact that granzyme B expression was
restricted to certain antigen-speciﬁc T-cell clusters. We also
detected a KLRG-1+ fraction among mAlg8-speciﬁc T cells that
was absent on mLama4-speciﬁc T cells. KLRG-1 on terminal
effector T cells has been shown to be involved in effective anti-
tumour reactions42. Thus, mAlg8-reactive T cells might be more
effective in carrying out distinct functions in anti-tumour
responses as compared with their mLama4 counterparts in
untreated tumour-bearing mice. Interestingly, upon anti-CTLA-4
treatment, a large number of KLRG-1+ cells could be found in
both mLama4- and mAlg8-reactive T cells. The preceding study
detected a similar pattern of Tim-3 and Lag-3 expression among
T cells speciﬁc for either mLama4 or mAlg8 antigen5. In contrast,
we detected different expression levels of markers associated with
dysfunction amongst both antigen-speciﬁc T cells. These phe-
notypic differences highlight the power of the t-SNE algorithm
combined with high-dimensional mass cytometry to disentangle
cellular subsets25 and supports the hypothesis of a different
functionality between T cells targeting different antigens in the
same tumour. Interestingly, GITR was also associated with all of
the dysfunctional clusters identiﬁed. GITR on regulatory T cells
has recently been described as a target for improved anti-tumour
responses in liver cancer43 and a combined treatment consisting
of anti-PD-1 and anti-GITR mAbs gave rise to anti-tumour
immunity in mice by enhancing CD8+ effector T-cell functions44.
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We (M.M.G., J.P.W. and R.D.S.) reported that checkpoint
blockade immunotherapy resulted in a functional re-activation of
mutant tumour antigen-speciﬁc T cells and this was accompanied
by successful tumour rejection5. Consistent with this, we did not
detect any of the pre-deﬁned dysfunctional clusters on mLama4-
and mAlg8-specﬁc T cells after CTLA-4 blocking. We made
similar observations on mLama4-speciﬁc TILs in mice that
underwent PD-1 blocking. As we cannot exclude that anti-PD-1
treatment resulted in blocking of this marker and thus making it
inaccessible for the further detection by the mass cytometry
staining, we excluded it from the t-SNE analysis. Nevertheless,
regardless of this PD-1 invisibility by t-SNE we found that cells
with differential expression levels of markers associated with
dysfunction disappeared following anti-PD-1 immunotherapy.
Notably, our results also showed that antigen-speciﬁc T cells in
response to anti-CTLA-4 or anti-PD-1 immunotherapy acquire a
similar novel phenotypic diversity. We observed higher
frequencies of Sca-1+ CD8+ cells in mice undergoing treatment.
Sca-1 was reported to be involved in T-cell development, as well
as T-cell activation and proliferation45, and thus may reﬂect an
activated status of neoantigen-speciﬁc T cells following check-
point blocking.
An ability to identify tumour neoantigens is likely to become
an important tool for personalized cancer immunotherapies1.
Evolving genomic and bioinformatics approaches reveal an
underappreciated diversity of potential mutant tumour epitope
candidates. In order to identify therapy-relevant neoantigens and
to understand the effects of immunotherapies on cells targeting
such antigens, we envision the requirement to simultaneously
analyse multiple tissues in a comprehensive approach similar to
that described here. Our results demonstrate a proof of concept
for the feasibility of probing a very large number of MHC-I
restricted neoepitopes in cancer by mass cytometry with the
simultaneous capacity to deeply proﬁle neoantigen-speciﬁc T cell
in the context of cancer immunotherapy. Importantly, our data
show that checkpoint blockade immunotherapy resulted in
remarkable phenotypic alterations speciﬁcally in neoantigen-
speciﬁc TILs that are not observed in peripheral neoantigen-
speciﬁc T cells. Hence, the characterization of peripheral neo-
antigen-speciﬁc T cells may not always mirror responses occur-
ring in the tumour, which should be an important consideration
for the possible use of peripheral T cell response as biomarkers of
therapeutic outcome.
Methods
Mice. 129S6/SvEvTac (129SVE-M) male mice aged 6–10 weeks were purchased
from InVivos (Singapore) and housed under speciﬁc pathogen-free conditions. All
experiments and procedures were approved by the Institutional Animal Care and
Use Committee (130879) of A*STAR (Biopolis, Singapore) in accordance with the
guidelines of the Agri-Food and Veterinary Authority, as well as the National
Advisory Committee for Laboratory Animal Research of Singapore.
Tumour cell transplantation and antibody treatment. MCA-induced sarcomas
were generated as described previously5. Brieﬂy, frozen cells from the subclonal
progressor cell line d42m1-T3 (developed by the R.D. Schreiber laboratory3) where
thawed from frozen stocks and expanded in vitro in RPMI media (Hyclone)
supplemented with 10% hiFCS, 1% L-glutamine, 1% penicillin–streptomycin, 1%
sodium pyruvate, 0.5% sodium bicarbonate and 0.5% 2-mercaptoethanol. Cells
were collected using trypsin (Hyclone), extensively washed in Hank’s balanced salt
solution (Hyclone) and eventually resuspended in endotoxin-free phosphate-buf-
fered saline (PBS; GIBCO) at a ﬁnal concentration of 6.67 × 106 cells per ml. For
inoculation, 150 μl of this solution were injected subcutaneously into the hind
ﬂanks of naive syngeneic recipient mice. Mice were monitored for tumour growth
every second day. Tumour growth was quantiﬁed by caliper measurements and
mice were killed by CO2 asphyxiation before the tumour size exceeded 20 mm. For
antibody therapy, mice were treated intraperitoneally with either 200 μg of anti-
CTLA-4 (murine IgG2b clone 9D9, BioXcell) or anti-PD-1 (murine IgG2a clone
RMP1-14, BioXcell) on days 3, 6 and 9 post-tumour transplant. For controls, mice
received either 200 µg IgG2b (clone MPC-11, BioXcell) or IgG2a (clone 2A3,
BioXcell) isotype control antibodies.
Tissue collection and processing. Twelve days post-tumour transplantation, mice
were killed by CO2 asphyxiation and tumours, spleens, draining lymph nodes and
non-draining lymph nodes were collected. Established solid tumours were excised
from the adjacent tissue, minced and incubated with 1 mgml−1 collagenase D
(Sigma), in complete medium for 1 h at 37 °C to make single-cell suspensions. The
cells were then ﬁltered through a 70 µm strainer (Miltenyi Biotec) and washed
before removing dead cells via a dead cell removal kit (Miltenyi Biotec). Spleens
were crushed, ﬁltered and red blood cell lysis was performed by hypotonic lysis.
Lymph nodes (draining and non-draining) were removed from mice, mashed and
resuspended to obtain single-cell solutions. To remove aggregates, all cells were
subsequently ﬁltered through a 70-μm strainer.
Antibody and streptavidin labelling. Puriﬁed antibody clones and providers are
listed in Supplementary Table 1. Recombinant streptavidin was expressed and
refolded in house as previously described23. Maleimide-conjugated DN3 MAXPAR
chelating polymers (Fluidigm) were loaded with heavy metal isotopes according to
the manufacturer’s recommendations. For antibody conjugations, 100 µg of pur-
iﬁed antibodies lacking carrier proteins were coupled at a time with the metal-
polymer structures according to the protocol provided by Fluidigm. For strepta-
vidin conjugations, 50 µg of streptavidin at a time was conjugated to the respective
metal-loaded DN3 polymer and ﬁnally diluted to a concentration of 200 µg ml−1
for subsequent tetramerization23, 46.
Peptides. Mutant tumour epitopes used in the present study are based on pre-
dicted binding afﬁnities using NetMHC 3.0 with an IC50 of <50 nM, as well as the
MHC class I epitope predictions as reported in ref. 5. All peptides were ordered
from Peptide 2.0, Inc. with a purity of at least 75% and were provided by Bob
Schreiber’s group from the Washington University in St. Louis, School of Medicine
(St. Louis, MO). Epitope sequences used in this study are listed in Fig. 1a and
Supplementary Table 2.
Peptide-MHC loading and tetramerization. Peptide–MHC complexes were
synthesized in house as previously described23. Brieﬂy, recombinant H-2Kb heavy
chains and human β2 microglobulin light chains were isolated from Escherichia coli
derived inclusion bodies and refolded in the presence of a UV-cleavable peptide
(SIINFEJL, Mimotopes) followed by subsequent biotinylation and puriﬁcation.
Speciﬁc peptide-MHC complexes were generated by UV irradiation (15 min,
365 nm) in the presence of single rescue peptides. Peptide exchange reactions were
setup in 96- well plates with 100 µl of 100 µg per ml H2Kb in PBS and 50 µM of
rescue peptides. Exchanged peptide–MHC complexes were stored at 4 °C for a
minimum of 12 h before tetramerization. For the generation of a combinatorial
triple-coded tetramer staining mixture, three out of nine differently metal-labelled
streptavidins were randomly combined at a time by using an automated pipetting
device (TECAN) resulting in a total of 84 possible combinations. For initial
screenings, we set up a second conﬁguration carrying a completely different
combination of metal-tagged streptavidin molecules as internal control. For tet-
ramerization, these mixtures were then incubated with the single exchanged
peptide–MHC complexes in the 96-well plates at a ﬁnal molar ratio of 1:4 (total
streptavidin:peptide–MHC). Each streptavidin combination was added in four
steps with 10 min incubation at room temperature (RT) to the peptide–MHC
complexes according to their afore determined coding schemes, followed by a ﬁnal
addition of 10 µM free biotin (Sigma). For each staining conﬁguration the tetra-
merized pMHC complexes were then combined and concentrated by using a 10
kDa (Merck Millipore) cutoff ﬁlter. We ﬁnally exchanged the buffer into cytometry
buffer (PBS, 2% fetal calf serum, 2 mM EDTA, 0.05% sodium azide) and ﬁltered the
tetramer cocktails before staining the cells with a concentration of ~ 500 nM per
peptide–MHC molecule.
Staining and data acquisition. Staining of samples was carried out as described
previously23, 25, 27. Brieﬂy, three to ﬁve million cells/tissue were transferred into 96-
well plates, washed once with cytometry buffer and incubated for 5 min on ice in
200 µM cisplatin (Sigma) for the discrimination of live and dead cells47. Cells were
washed twice and each sample was stained with 50 µl of tetramer cocktail for 1 h at
RT. Subsequently, cells were washed twice and then incubated with 50 µl of heavy
metal-labelled antibody cocktail (Supplementary Table 1) for 30 min on ice fol-
lowed by ﬁxing the cells in 2% paraformaldehyde (Electron Microscopy Sciences)
in PBS overnight or longer at 4 °C. The cells were then washed once in 1× per-
meabilization buffer (Biolegend) and each sample was then barcoded with a unique
combination of two distinct barcodes consisting of either bromoacetamidobenzyl-
EDTA (Dojindo)-linked metal barcodes (Pd-102, Pd-104, PD106 and PD108, and
Pd-110) or DOTA-maleimide (Macrocyclics)-linked metal barcodes (LN-113) for
30 min on ice25, 27. Cells were washed once, incubated in cytometry buffer for 5
min and subsequently resuspended in 250 nM iridium intercalator (Fluidigm) in
2% paraformaldehyde/PBS at RT. The cells were washed and the samples from
each tissue were pooled together and adjusted to 0.5 million cells per ml H2O
together with 1% equilibration beads (EQ Four element calibration beads, Flui-
digm) for acquisition on the mass cytometer27.
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Flow cytometry staining. H-2Kb peptide-MHCI complexes with mLama4 or
mAlg8 peptides were prepared by UV-induced ligand exchange as described above
and tetramerized by three additions of streptavidin conjugated to either phycoer-
ythrin or allophycocyanin (Biolegend) to achieve the ﬁnal molar ratio of 1:4 (total
streptavidin:peptide–MHC). Cells were stained with tetramers and Fc block (anti-
CD16/32, BD Bioscience) in PBS 0.5% BSA at 4 °C for for 1 h at RT. Subsequently,
cells were washed and then stained with ﬂuorescently conjugated antibodies to PD-
1 (29 F.1A12, Biolegend 1/100), KLRG1 (2F1, Biolegend 1/100), CD8 (53–6.7,
Biolegend 1/100), Sca-1 (D7, Biolegend 1/100), TCR-beta (H57-597 Biolegend 1/
100), CD27 (LG.7F9, Biolegend 1/100) and Tim-3 (B8.2C12, Biolegend 1/100), and
Live–dead (Thermo-Fisher—L34957) at 4 °C for 15 min, followed by washing and
incubation in FoxP3 ﬁxation buffer (eBioscience) for 30 min on ice. After washing
in permeabilization buffer (eBioscience), the cells were then stained with Ki-67
(11F6, Biolegend 1/100) and granzyme B (GB7, Biolegend 1/100) antibodies in
permeabilization buffer for 30 min on ice. All ﬂow cytometry experiments were
performed on a FACSCalibur device (BD Biosciences) and analysed using FlowJo.
Data analysis. Mass cytometry data were analysed as previously described25, 27, 48.
First, the signal of each parameter was normalized based on the equilibration beads
added to each sample49. The zero values of the.fcs ﬁles were randomized by an R-
script that uniformly distributes values between minus-one and zero. Each barcode
combination was deconvolved manually followed by gating on live CD8+ T cells
using FlowJo software (Treestar, Inc.). Antigen-speciﬁc triple-tetramer-positive
cells were further identiﬁed by an automated gating strategy23 and subsequently
validated by manual gating using Flowjo. For the detection of triple-tetramer-
positive cells, we set a cut off at a frequency of 0.15% for all CD8+ T cells, as signals
became random below this threshold. For t-SNE dimensionality reduction, the cell
events of all tissues were down-sampled to a maximum number of 10,000 CD8+
T cells per tissue. t-SNE analysis was carried out by using an R-package27 including
the “ﬂowCore” and “Rtsne” CRAN R packages for an efﬁcient implementation of t-
SNE via the Barnes-Hut approximations)24, 26. For automated clustering, we per-
formed k-means clustering of the t-SNE output, using 10 centres and 1,000 random
repeats. The χ2-test was used to assess the correlation between the two grouping
methods.
In R, all data were transformed using the “logicleTransform” function by using
the “ﬂowCore” package (parameters: w= 0.25, t= 16,409, m= 4.5, a= 0). We
calculated the percentages and median intensity values for each marker assessed
and used heat maps to represent marker expression and to identify the
characteristic markers of each cluster. Pie charts and bar graphs shown in this
manuscript were generated using Graphpad Prism software and heat plots were
generated using custom R-scripts.
Statistical analysis. Statistical comparisons for continuous variables between two
groups were done by Student’s t-test with pooled variance and Holm–Sidak pro-
cedure for multiple comparisons, or Fisher’s exact test for categorical variables. For
more than two groups analysis of variance was used followed by Holm–Sidak’s
multiple comparisons test. For a given marker, we computed Z-scores by per-
forming the transformation X signiﬁcance of X→ (X−m)/s, where X is the
expression of the marker across tetramer-positive cells, m its mean and s its SD23.
Signiﬁcance of Z-scores was analysed by t-tests followed by Benjamini–Hochberg
multiple test correction using a false discovery rate threshold of 0.2525, 27.
Data availability. Data that support the ﬁndings of this study are available through
the Flow Repository (http://ﬂowrepository.org/id/FR-FCM-ZY8A). All other data
are available from the authors on reasonable requests.
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